Table 2.
Summary of clinical studies that investigated the effectiveness of fenretinide in the treatment of PC (published between 2009 and 2021).
| Number of PC Cases | Patients | Dose of Fenretinide |
Duration of the Study |
Study Endpoints | Results | Reference |
|---|---|---|---|---|---|---|
| 23 | Patients with PSA ≥2 ng/mL after radical prostatectomy and/or radical radiotherapy (with metastases excluded). Ethnicity: Americans Age: 69 years (median) |
900 mg/m2 of body surface area twice daily for 1 week every 3 weeks | 1 year, follow-up: 17.7 months (median) |
PSA decline ≥50% or ≥5 ng/mL PSA-stable disease Time to PSA progression Probability of no PSA-progression in 6 months |
0% 30% (95%CI: 14–52%) 4.6 months (95%CI: 3.2–8.2) 0.37 ± 0.10 |
Cheung et al., 2009 [60] |
| 27 | Patients after castration with rising PSA >10 ng/mL. Ethnicity: Australians, Asians Age: 74 years (median) |
900 mg/m2 of body surface area twice daily for 1 week every 3 weeks | 1 year | PSA decline >50% for at least 3 weeks PSA-stable disease for 6 weeks Time to treatment failure (PSA-based assessment) |
4% (maximum of 39 days) 52% 54 days |
Moore et al. 2010 [58] |
Abbreviations: PC—prostate cancer, PSA—prostate specific antigen.